Article Details
Retrieved on: 2024-01-05 21:48:51
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for cancer, filed on Friday with the SEC to raise up to $100 million in ...
Article found on: www.renaissancecapital.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here